|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total PACS population(n = 567) | Vaccinated population (n = 397) | Non-vaccinated population (n = 170) | p-valuevaccinated vs. Non-vaccinated |
| Female sex, % (n) | 83.4% (473) | 85.9% (327) | 82.4% (146) | *ns* |
| Age, median (IQR) | 44 (37-50) | 44 (37-50) | 42 (36-49) | *ns* |
| COVID-19 severity* Home-care
* Hospitalized with oxygen therapy
	+ Intensive care unit
 | 94.9% (538)5.1 (25)0.7% (4) | 95.3% (376)4.7 (18)0.8% (3) | 94.7% (162)5 3 (7)0.6% (1) | *ns* |
| Confirmed COVID-19, % (n)* Positive RT-PCR
* Positive lung CT
* Positive serology
* Positive antigen test
 | 64.4% (365)45% (255)22.8% (129)32.3% (183)8.6% (49) | 63% (250)43.1% (171)22.2% (88)30.2% (120)8.1% (32) | 67.7% (115)49.4% (84)24.1% (41)37.1% (63)10% (17) | *ns* |
| Time since initial COVID-19, days, median (IQR) | 475 (261-506) | 483 (266-506) | 325 (180-507) | **0.0066** |
| Number of persisting symptoms, median (IQR) | 12 (9-15) | 12 (9-15) | 13 (10-15) | *ns* |
| Professional activity* Unchanged
* Adapted to PACS
* Interrupted
 | 45% (255)18% (102)37% (210) | 47.4% (188)19.4% (77)33.3% (132) | 39.4% (67)14.7% (25)45.9% (78) | **0.016** |
| Vaccination* Time since initial infection
* Doses
	+ One
	+ Two
 | - | 357 [198-431]64.2% (255)35.8% (142)  | -- | N/A |

**Supplementary Table 1: Characteristics from the included population.**

Lung CT, lung computed tomography; PACS, post-acute COVID-19 syndrome; RT-PCR, reverse transcriptase polymerase chain reaction



**Supplementary Figure 1. Evolution of reported symptoms following vaccination.**